Next Article in Journal
Evaluating Cardiotoxicity in Breast Cancer Patients Treated with HER2 Inhibitors: Could a Combination of Radionuclide Ventriculography and Cardiac Biomarkers Predict the Cardiac Impact?
Next Article in Special Issue
Plasma Extracellular Vesicle Characteristics as Biomarkers of Resectability and Radicality of Surgical Resection in Pancreatic Cancer—A Prospective Cohort Study
Previous Article in Journal
Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
Previous Article in Special Issue
Circulating Long Non-Coding RNAs Could Be the Potential Prognostic Biomarker for Liquid Biopsy for the Clinical Management of Oral Squamous Cell Carcinoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 1
10.3390/cancers15010205
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Serum-Exosome-Derived miRNAs Serve as Promising Biomarkers for HCC Diagnosis

by
Tao Rui
1,2,*,
Xiaobing Zhang
1,2,
Jufeng Guo
1,
Aizhai Xiang
1,
Ning Tang
1,
Jian Liu
1 and
Zonglei Mao
1,2,*
1
Department of Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
2
The Center for Integrated Oncology and Precision Medicine, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
*
Authors to whom correspondence should be addressed.
Cancers 2023, 15(1), 205; https://doi.org/10.3390/cancers15010205
Submission received: 29 November 2022 / Revised: 23 December 2022 / Accepted: 25 December 2022 / Published: 29 December 2022
(This article belongs to the Special Issue Promising Biomarkers in Liquid Biopsy of Cancer)
Browse Figures
Review Reports Versions Notes

Abstract

Simple Summary

We aim to discover the ideal biomarkers for diagnosing HCC, by detecting the small RNAs (sRNAs) from serum exosomes. After analyzing the proportion and distribution of sRNAs species from serum exosomes, we found that miRNAs were the most important components in serum exosomes. Three serum-exosome-derived miRNAs (miR-122-5p, let-7d-5p, and miR-425-5p) had significant values for diagnosing HCC, both in the training set and validation set. Our results concluded that serum-exosome-derived miRNAs could be the promising biomarkers in HCC diagnosis

Abstract

Background: Serum exosomes are emerging as key liquid biopsy biomarkers for the early diagnosis of cancer. However, the proportion and distribution of small RNA (sRNA) species from serum exosomes of hepatocellular carcinoma (HCC) patients remain unclear. Effective and reliable biomarkers for HCC diagnosis should be explored. Methods: In this study, we aimed to use sRNA sequencing to profile the sRNAs of serum exosomes in HCC and non-tumor donors. The serum exosomes of 124 HCC patients and 46 non-tumor donors were enrolled for detecting the values of the potential biomarkers for the diagnosis of HCC. Results: We found that miRNAs accounted for the maximal percentage of all types of sRNAs both in the serum exosomes of HCC patients and non-tumor donors. This indicated that the serum-exosome-derived microRNAs (miRNAs) were the most valuable as potential biomarkers in HCC diagnosis. Then, miRNAs were set as research candidates. In our Chinese cohorts, three serum-exosome-derived miRNAs (miR-122-5p, let-7d-5p, and miR-425-5p) could be promising biomarkers for distinguishing HCC patients from non-tumor donors. In addition, they were preferred for the early diagnosis of HCC. We also presented the base distribution of some novel serum-exosome-derived miRNAs and described the potential values as biomarkers. Conclusions: The results suggested that the serum-exosome-derived miRNAs were the most crucial sRNA species and they highlighted the potential of serum-exosome-derived miRNAs as promising biomarkers for HCC diagnosis.

1. Background

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide. Although great advances have been achieved in the therapeutic strategy, HCC-related mortality has increased. Finding effective and rapid screening tools for diagnosing HCC is essential. Serum alpha-fetoprotein (AFP) measurement is the unique marker that is broadly recommended for the screening of HCC. However, long-term data indicate that the sensitivity of AFP for hepatocellular cancer only ranges from 41% to 65% [1]. The breakthrough of serum markers for the in-clinic fast screening of HCC is limited. Thus, it is essential and urgent to discover ideal markers for the early diagnosis of HCC.
Exosome, as the kind of nanoscale vesicle produced from living cells, is a rising star in tumor liquid biopsy [2,3,4]. Exosome-based liquid biopsy is a promising technological advancement for cancer diagnosis [5,6,7]. Tumor-related serum exosomes are excreted from living tumor cells [8,9]. In addition, the serum exosomes can be acquired with less invasiveness. This means that continuous information from tumors could be acquired from serum exosomes in real time [10]. Moreover, the phospholipid bilayer membranes of exosomes contribute to the regulation of membrane dynamics for exosome release [11]. The phospholipid bilayer also prevents the degradation of exosomal contents [12]. Thus, signals emitted from tumor cells can be well stored and transferred via exosomes.
Small RNAs (sRNAs) are one of main components that exist in the exosomes [13]. Various sRNAs have been found in human-generated exosomes, including microRNAs (miRNAs), transfer RNAs (tRNAs), ribosomal RNAs, piwi-interacting RNA (piRNAs), and other unidentified RNAs. During the last two decades, a plethora of studies have confirmed that exosome-derived sRNAs have crucial value in tumor diagnosis and prognosis prediction [14,15,16]. The components of serum exosomes, such as long noncoding RNAs (lncRNAs), circle RNAs, and miRNAs have also been shown to be potential biomarkers for the diagnosis of HCC [17]. However, the proportion and distribution of sRNAs in serum exosomes of HCC are not understood, and this is critical for exploring effective tumor biomarkers. To date, no excellent exosome-derived biomarkers for diagnosing HCC have been used in clinical applications. In this study, we showed the specificity of HCC serum-exosome-derived sRNAs species and exhibited that miRNAs were the most crucial components in serum-exosome-derived sRNAs. Additionally, we introduced the top three serum-exosome-derived miRNAs as optimal biomarkers for diagnosing HCC in the clinic.

2. Materials and Methods

2.1. Patients and Specimens

To avoid the influence of medical interventions on serum-exosome-derived sRNA levels, all of the samples used in this study were collected prior to the patients receiving hepatectomy, tumor invasive biopsy, or any forms of tumor therapy. After the patient was diagnosed with HCC according to histopathologic examination, the collected samples from the patients could be enrolled. Finally, the serum of 127 HCC patients and 46 non-tumor donors was enrolled. Three samples were excluded from this study (one of them was accompanied by duodenal cancer and two underwent adjuvant therapy from an outside hospital before serum collection and tissue biopsy). Thus, 124 cases of HCC serum were prepared for exosome purification. The characteristics of HCC patients are shown in Supplementary Material S1 Table S1. Among them, 34 (27.4%) were female and 90 (72.6%) were male, with the mean age of 59.60 ± 8.56 years. Ninety-four (75.8%) had a positive hepatitis B virus (HBV) infection, and thirty (24.2%) were of HBV-negative status. The histological stage of the HCC patients was assessed according to the 8th Edition of American Joint Committee on Cancer; the tumor, node, metastasis classification (AJCC-TNM) [18]. Of these, 65 (52.4%) had a low AJCC stage (stage I and II) and 59 (47.6%) had a high AJCC stage (stage III and IV). This research protocol was approved by the Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine. The participants provided written informed consent to participate in this study.

2.2. Serum Exosome Purification and Exosome RNA Extraction

As previously described [19], before exosome extraction, the serum from HCC patients and non-tumor donors was centrifuged at 3000× g at 4 °C for 5 min and filtered with a Millex GV filter unit (0.22 μm, Merck Millipore, Darmstadt, Germany). Serum exosome purification and exosome RNA extraction from 1 mL of serum were performed by using an exoRNeasy Midi Kit (No. 77144, Qiagen, Hilden, Germany), according to the manufacturer’s instructions.

2.3. sRNA-Sequencing Analysis

sRNA sequencing analysis was used to screen the potential serum-exosome sRNAs for HCC diagnosis. After the candidates are selected, qRT-PCR should be further performed in large samples to conclude that the candidates could be used as ideal biomarkers. Thus, four HCC patients and four non-tumor donors were randomly selected for the sRNAs-sequencing analysis. The characteristics of the four patients and four non-tumor donors are shown in Supplementary Material S1 Table S2. The sRNA-sequencing was performed by using the Multiplex Small RNA Library Prep Set for Illumina® (San Diego, CA, USA) at the Novegene Bioinformatics Technology Co., Ltd. (Beijing, China), according to the manufacturer’s instructions. For annotating exosome sRNAs, the sRNAs were filtered from clean reads according to the range of length. The sRNA tags were mapped and matched to genome version CRCh38 by the short read aligner named as Bowtie [20]. For identifying the known miRNAs, the sRNAs were mapped with miRBase20.0 [21]. For predicting novel miRNAs, the available software miREvo and mirdeep2 were integrated [22,23]. Differentially expressed miRNAs between HCC patients and non-tumor donors were performed by using the DESeq R package. The log2 fold change > 1 and false discovery rate (FDR) (adjusted p value) < 0.05 were set as the threshold for distinguishing differentially expressed miRNAs.

2.4. Exosome Identification

We prepared the exosome identification by transmission electron microscope (TEM) and nanoparticle tracking analysis (NTA). As previously described [19], the purified exosomes from the serum of HCC patients and non-tumor donors were negatively stained with phosphotungstic acid (2%) on a copper grid for 1.5 min and dried for 15 min. The exosomes were observed with a TEM (Tecnai G2 Spirit 120 kV, Thermo Fisher Scientific, Waltham, MA, USA). The TEM was operated by the core facility platform of Zhejiang University. The NTA was performed with the Nano-ZS90 instrument (Malvern, UK), according to the manufacturer’s instructions, for measuring the hydrodynamic diameter distribution of exosomes.

2.5. Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR)

As previously described [24], stem-loop miRNA qRT-PCR was performed for detecting the expression of miRNAs. According to the Bulge-Loop miRNA qRT-PCR Starter Kit (C10211, Ribobio, Guangzhou, China), specific reverse transcription primers were used to synthesize cDNA. PCR amplification was performed with FS Essential DNA Green Master (4913914001, Roche, Basel, Switzerland) accompanied by the LightCycler480 instrument (Roche, Basel, Switzerland). The data from the qRT-PCR were performed in replicates of three. The primers are listed in Supplementary Material S1 Table S3.

2.6. Western Blot Analysis

As previously described [19], the total proteins were extracted from the purified exosomes. After the proteins were denatured, they were electrophoresed on sodium dodecyl sulfate–polyacrylamide gel electrophoresis SDS-PAGE gel (FD341-100, Fudebio, Hangzhou, China) and transferred onto equilibrated polyvinylidene difluoride membranes. The membranes were then blocked for 1 h at room temperature and incubated with primary antibodies overnight at 4 °C. Before being detected by an enhanced chemiluminescence (ECL) system (Biotanon, Shanghai, China) with FDbio-FemtoECL (FD8030, Fudebio, Hangzhou, China), the membranes were incubated with a secondary anti-rabbit immunoglobulin G (IgG) horseradish peroxidase (HRP)-linked antibody. The antibodies are listed in Supplementary Material S1 Table S4.

2.7. Statistical Analysis

Mean ± standard deviation (SD) or median ± interquartile range (IQR) was used for the description of the quantitative variables. The Student’s t-test or the Mann–Whitney test were performed to analyze the comparison of quantitative variables between the two groups. The analysis of variance (ANOVA) followed by Newman–Keuls individual comparisons were used among more than two groups. Categorical measures were compared by the chi-square test or Fisher’s exact test. The area under receptor operated curve (AUROC) mode and the diagnostic performance characteristics were used to calculate the diagnostic values of miR-425-5p, let-7d-5p, and miR-122-5p in HCC. Statistical analysis was performed with Statistical Product and Service Solutions (SPSS) software (version 19.0, IBM, Armonk, NY, USA), and the p value < 0.05 was set as the significance level. *, **, ***, and **** were used to represent p value of < 0.05, < 0.01, < 0.001, and < 0.0001, respectively.

3. Results

3.1. Profiling and Analyzing of Exosome-Derived Small RNAs in the Serum of HCC Patients

First, the serum exosomes from HCC patients and non-tumor donors were isolated (Figure 1A). The TEM observed the typical membrane structure of the exosomes with a diameter of less than 100 nm (Figure 1B). The hydrodynamic diameter distribution of serum exosomes from HCC patients and non-tumor donors was shown (Supplementary Material S1 Figure S1). After extracting the proteins of the exosomes, we detected four classic protein markers of exosomes (CD9, CD63, TSG101, and HSP70) by Western blot analysis (Figure 1C and Figure S11). Thus, the exosomes were successfully extracted from serum.
We further prepared the sRNAs’ sequencing. The sequencing error rate of each base was less than 0.05%, which suggested that the sequencing results were of high quality (Supplementary Material S1 Figure S2). By analyzing the proportions of the components of sRNAs (miRNA, tRNA, rRNA, snRNA, and snoRNA) in the serum exosomes, we markedly observed that miRNAs were the kind of sRNAs with the largest numbers, compared with the others (Figure 1D). Notably, the proportions of miRNAs were greater than 50%, and 40% in the HCC-derived serum exosomes and non-tumor donor-derived serum exosomes, respectively (Figure 1D). The results suggested that miRNAs were the critical component in serum-exosome-derived sRNAs. Interestingly, the length distributions of the sRNAs exhibited high concordance. The sRNAs with a length of 19–22 nucleotides (nt) had significant peaks, both in the serum exosomes of HCC patients and NT donors. In addition, miRNA is characterized by the length of 18–22 nt (Figure 2). Therefore, serum-exosome-derived miRNAs were the main components of sRNAs and might serve as the key biomarkers for clinical applications.

3.2. Three Serum-Exosome-Derived miRNAs Acted as Accurate Biomarkers for the Diagnosis of HCC

Since miRNAs were the most important components in serum exosomes, we further explore the value of serum-exosome-derived miRNAs in the diagnosis of HCC. We firstly detected the base distribution. No significant base distribution bias was observed in the serum-exosome-derived miRNAs between the HCC and non-tumor donors (Supplementary Material S1 Figure S3). This represented that the serum-exosome-derived miRNA species had no specificity in HCC. Then, we profiled the serum exosome-derived miRNAs (Supplementary Material S1 Figure S4) and detected the differences in the expression levels of specific miRNAs. At the threshold criteria set as log2 fold change > 1 and FDR < 0.05, we screened 30 differentially expressed miRNAs (11 miRNAs were upregulated and 19 miRNAs were downregulated) (Supplementary Material S2). Therefore, we successfully identified the differences in exosome-derived miRNA expression profiles between HCC and non-tumor donors. Interestingly, among the differentially expressed miRNAs, the miRNAs spliced from the 5’ of the precursor miRNAs accounted for the majority. We identified that 72.7% (8/11) of the upregulated miRNAs and 68.4% (13/19) of the downregulated miRNAs were from 5’ of the precursor miRNAs (Supplementary Material S2).
Among these differentially expressed miRNAs, we selected three miRNAs (miR-122-5p: 1.2675 × 10−7; let-7d-5p: 0.0023; miR-425-5p: 0.0043) with the top three highest statistical significances as study candidates, according to the rank of FDR values (Figure 3A and Supplementary Material S2). To further confirm the three potential biomarkers, we purified serum exosomes and extracted sRNAs from 124 HCC patients and 46 non-tumor donors. To increase the reliability of the results, the samples were divided into a training set and a validation set. From the training set (55 HCC patients and 20 non-tumor donors), three miRNAs were all significantly upregulated in HCC-derived serum exosomes (Figure 3B–D). To calculate the values of the three serum-exosome-derived miRNAs in the diagnosis of HCC, we introduced the levels of the three miRNAs into AUROC mode. The AUROC values of miR-122-5p, let-7d-5p, and miR-425-5p for predicting the diagnosis of HCC were 0.808, 0.702, and 0.660, respectively (Figure 3E,F). If we combined the levels of the three miRNAs, the AUROC value was notably up to 0.905 (Figure 3E,F).
From the training set, the diagnostic performance characteristics of the three miRNAs in diagnosing HCC were shown in Supplementary Material S1 Table S5. The results from the validation set (69 HCC patients and 24 non-tumor donors) also showed that miR-122-5p, let-7d-5p, and miR-425-5p increased significantly in the serum exosomes from HCC, compared with those from non-tumor donors (Figure 4A–C). miR-122-5p, let-7d-5p, and miR-425-5p increased 6.35-fold, 3.10-fold, and 2.12-fold, respectively. The AUROC mode also presented that the three miRNAs had high values in HCC diagnosis (Figure 4D,E). The diagnostic performance characteristics from the validation set are shown in Supplementary Material S1 Table S5. The results were consistent with those from the training set. The diagnostic value of the traditional biomarker AFP in our Chinese cohorts was also calculated. The 3-miRNA signature showed a significantly higher diagnostic value, compared with AFP with a cutoff of 100 ng/mL or 400 ng/mL (Supplementary Material S1 Figure S5). Interestingly, if we divided the patients according to the AFP, we found that three miRNAs had higher diagnostic values in the cohort with an AFP larger than 100 ng/mL (Supplementary Material S1 Figure S6). The results demonstrated that three serum-exosome-derived miRNAs could be novel biomarkers for HCC diagnosis. By detecting the expression of serum-exosome-derived miR-425-5p, miR-122-5p, and let-7d-5p from 1ml serum, HCC might be accurately and rapidly diagnosed.

3.3. Three Serum-Exosome-Derived miRNAs Were Preferred for the Early Diagnosis of HCC

We also attempted to evaluate the value of the three serum-exosome-derived miRNAs for predicting HCC disease progress or tumor burdens. However, the results showed that three serum-exosome-derived miRNAs were not significantly correlated with tumor size, tumor number, macrovascular invasion, T-stage, AJCC-stage, and the AFP value of HCC (Supplementary Material S1 Table S6). This indicated that HCC patients with a low tumor stage or tumor burden could also express the three serum-exosome-derived miRNAs. Thus, three serum-exosome-derived miRNAs had potential value for the early diagnosis of HCC.
Then, we detected the application of the three serum-exosome-derived miRNAs for the early diagnosis of HCC. First, the expression levels of the three serum-exosome-derived miRNAs in the low stage of HCC were also significantly higher than those in non-tumor donors (Figure 5A–C). The upregulated fold-changes of miR-122-5p, let-7d-5p, and miR-425-5p were 17.51, 13.88, and 2.36 in the serum exosome of HCC with low-stage, respectively. AUROC mode showed that all three serum-exosome-derived miRNAs could accurately diagnose HCC at its early stage. If we combined the three miRNAs, the AUROC value was up to 0.923 (Figure 5D). Interestingly, compared with the values in the patients with high-stage HCC, the AUROC values in the patients with low-stage HCC were also higher (miR-122-5p: 0.843 vs. 0.791; miR-425-5p: 0.709 vs. 0.599; let-7d-5p: 0.767 vs. 0.589; 3-miRNA signature: 0.923 vs. 0.852; Figure 5D,E). The results from the other patient set also showed that the three miRNAs have significant values in diagnosing HCC at the early stage (Supplementary Material S1 Figure S7). Therefore, the three serum-exosome-derived miRNAs were also valuable when the patients suffered from early stage HCC.

3.4. Novel HCC Serum-exosome-derived miRNAs’ Identification

When mapping and annotating the sequences of sRNAs, a number of sRNAs failed to be defined, which suggested that new miRNAs might exist and could be used for the diagnosis of HCC. Thus, we performed the first attempt to identify the novel miRNAs in serum exosomes. As a result, 46 novel miRNAs candidates were identified (Supplementary Material S3). Novel miR-224, novel miR-286, and novel miR-300 were the three novel miRNAs with the most significant difference in HCC serum exosomes (Supplementary Material S1 Figure S8). The structures of the three novel miRNAs are shown in Supplementary Material S1 Figure S9. The analysis of base distribution also showed specific performance. In the serum exosome of HCC, the peak of base A distribution appeared in the middle of the miRNA sequence (Supplementary Material S1 Figure S10). However, in the serum exosome of non-tumor donors, the distribution of base A at the head and tail of novel miRNAs (5’ and 3’) increased significantly (Supplementary Material S1 Figure S10). In addition, a low proportion of base G existed in the novel miRNAs of the HCC serum exosome (Supplementary Material S1 Figure S10). The results suggested that the serum-exosome-derived novel miRNAs in HCC significantly differed from those of the non-tumor donors. However, the diagnostic value and the mechanisms of the novel miRNAs in the serum exosomes of HCC need further investigation.

4. Discussion

Liquid biopsy is a new concept compared with tissue biopsy [25]. At present, tumor tissue biopsy remains the gold standard in tumor diagnosis. However, it does have many defects in the clinic. First, patients must suffer invasiveness during traditional tissue biopsy. Second, tissue biopsy has the potential risk of causing needle tract seeding or dissemination of the tumor [26,27]. Third, tumor heterogeneity also reflected that limited samples from tissue biopsy fail to better collect the complete information of the whole tumor. Thus, increasing interest has been provoked during the practice of blood liquid biopsy. Malignant tumors are characterized by an abundant blood supply, unrestricted proliferation, and invasive behavior [28,29]. This indicates that much more information can be transferred into the blood from tumor cells. Exosomes act as cargo for transferring the contents that contribute to the transmission of cellular information, such as sRNAs, lipids, metabolites, and proteins [30,31]. To date, serum exosome-based liquid biopsy has been widely reported for the diagnosis of many types of human cancers. Serum exosomes can be isolated and obtained efficiently, and the information from serum exosomes could reflect the status of cancers in real time.
It is well known that serum exosomes contain a variety of sRNAs [32,33]. In addition, the contents of exosomes have the potential to be used for the diagnosis of cancer [34,35,36]. Sorop A et al. reviewed that some exosome-derived miRNAs could be used in the diagnosis of HCC [37]. Exosomal tRNA-derived small RNAs (tsRNAs) also could be the novel diagnostic biomarkers for HCC [38]. However, all the above studies could not present the proportion of sRNAs in serum exosomes from HCC, which is crucial for discovering valuable tumor biomarkers. In our study, we successfully found that miRNAs were the absolutely critical component, compared with other types of exosome-derived sRNAs. However, the reason why HCC cells released abundant miRNAs via exosomes remains unexplained.
Our study aimed to discover the optimal serum-exosome-derived biomarkers for effective diagnosis of HCC. Some reports have confirmed that miR-224, miR-21, miR-210-3p, miR-93 and miR-155 were upregulated in the exosomes of HCC patients. Xue X et al. also discovered three upregulated miRNAs through exosomal miRNA profiling [39]. Our study confirmed that serum-exosome-derived miR-425-5p, miR-122-5p, and let-7d-5p showed high values in HCC diagnosis. In addition, they were preferred for the diagnosis of early-stage HCC. Although the diagnostic values of the three miRNAs in HCC have never been reported before, they do play a role in tumor regulation. LncRNA SNHG7 promoted the malignancy of HCC by regulating miR-122-5p [40]. MiR-425-5p promoted proliferation and migration of HCC by targeting FOXD3 and RNF11 [41,42]. Let-7d-5p facilitated cisplatin chemosensitivity of ovarian cancer by silencing HMGA1 via the p53 signaling pathway [43]. However, in this study, the question of why the early stage HCC patients released the three exosome-derived miRNAs much more was not concluded. It may involve the complex mechanism of tumor exosomes including miRNA synthesis, exosome production, exosome transfer and release. Alternatively, the three miRNAs act as “pivotal materials” in HCC cells, which contributes to HCC development. Thus, the HCC cells with high malignancy reject to release the three miRNAs or the feedback pathways exist in the malignant HCC that negatively control the synthesis of the three miRNAs. This is worth further investigation.
In addition to the currently known miRNAs, we identified the novel miRNAs that exist in exosomes. Many tools have been developed to mine new miRNAs through bioinformatics approaches [44,45]. Based on the miRNA length, miRNA biogenesis, and stem-loop hairpin secondary structure, several sRNA sequences were recognized as novel serum-exosome-derived miRNAs in this study. We also found that the expression of the novel serum-exosome-derived miRNAs had significant differences between HCC and non-tumor donors. the base distribution of the new miRNAs also had particular features. The distribution of base A had significant differences in the novel serum-exosome-derived miRNAs between HCC patients and non-tumor donors. Meanwhile, base G was not affluent in the serum-exosome-derived novel miRNAs in HCC patients. Thus, we have provided a new insight in that the base distribution of novel miRNAs in serum miRNAs could also work for HCC diagnosis.
There were limitations to this study. The specific mechanisms by which the three miRNAs were upregulated in serum exosomes of HCC deserve attention. The novel serum-exosome-derived miRNAs should also be further explored in a follow-up study. In addition, the results should be validated from other races. The specificity of the three biomarkers should be tested in patients with other forms of cancer or liver tumors.

5. Conclusions

In summary, this study focused on the value of in-clinic serum exosomes. We uncovered that miRNAs were the most crucial and valuable sRNAs of serum exosomes. Three serum-exosome-derived miRNAs (miR-122-5p, let-7d-5p, and miR-425-5p) could be practical and accurate biomarkers for HCC diagnosis. They also showed greater values for the diagnosis of early-stage HCC. The identified novel serum-exosome-derived miRNAs could also have the potential for clinical applications as biomarkers for HCC diagnosis. Specifically, exploring serum-exosome-derived miRNAs for diagnosing HCC is promising (Scheme 1).

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers15010205/s1, Supplementary Materials S1: Figure S1: The hydrodynamic diameter of serum exosomes extracted from HCC patients and non-tumor donors. Figure S2: The error rate of each base less than 0.05% representing the high quality of sRNAs sequencing. Figure S3: Base bias of serum-exosome-derived miRNAs from four HCC patients and four non-tumor donors. Figure S4: The heatmap depicts the expression of serum-exosome-derived miRNAs from HCC patients and non-tumor donors. Figure S5: The area under the receptor-operated curve (AUROC) values of the three serum-exosome-derived miRNAs and AFP with a cutoff of 100 ng/mL or 400 ng/mL in the diagnosis of HCC. Figure S6: The area under the receptor-operated curve (AUROC) values of the three serum-exosome-derived miRNAs in the diagnosis of HCC with high and low AFP. Figure S7: The area under the receptor-operated curve (AUROC) values of the three serum-exosome-derived miRNAs in the diagnosis of HCC with a low and high stage (training set). Figure S8: The volcano plot depicts differentially expressed novel miRNAs between four HCC patients and four non-tumor donors. Figure S9: The structure of the three differentially expressed novel miRNAs. Figure S10: Base bias of novel miRNAs from serum exosomes in four HCC patients and four non-tumor donors. Figure S11: The Original whole Western blot. Table S1: The characteristics of 124 HCC patients. Table S2: The characteristics of four randomly selected patients for sRNA-sequencing. Table S3: The sequences of primers for miRNA amplification. Table S4: The antibodies for Western blot. Table S5: The diagnostic performance characteristics from three miRNAs in the training set and validation set. Table S6: The correlation between three exosome-derived miRNAs and clinicopathological characteristics of HCC. Supplementary Materials S2: Differentially expressed serum-exosome-derived miRNAs in HCC vs. non-tumor donors. miR-122-5p, let-7d-5p, and miR-425-5p are the three serum-exosome-derived miRNAs with the most significant differences. Blue is used to mark the miRNAs with a false discovery rate (FDR) < 0.05, and red is used to mark the miRNAs from 5’ of the precursor miRNAs. Supplementary Materials S3: Novel serum-exosome-derived miRNAs in HCC vs. non-tumor donors (sheet 1). The sequences of novel identified miRNAs (sheet 2).

Author Contributions

T.R. and Z.M. designed the theme and organized the research. T.R. and Z.M. conducted the sample collection. T.R. and Z.M. performed the experiments. A.X., J.G., N.T., J.L. and X.Z. contributed to the data analysis. T.R., X.Z. and Z.M. prepared the original draft. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the Zhejiang Provincial Natural Science Foundation of China (Q23H160130) and the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission, China (2023RC224).

Institutional Review Board Statement

This study was approved by the Ethical Committee of Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine (protocol code: 2021 Research Ethics Review No. (174) and date of approval: 22 July 2021).

Informed Consent Statement

All participants provided their written informed consent to participate in this study.

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that there are no competing interests.

Abbreviations

HCC: hepatocellular carcinoma; AFP: alpha-fetoprotein; sRNAs: small RNAs; miRNA: microRNAs; piRNA: piwi-interacting RNA; snRNA: small nuclear RNA; lncRNA: long noncoding RNAs; HBV: hepatitis B virus; TEM: transmission electron microscope; NTA: nanoparticle tracking analysis; qRT-PCR: quantitative reverse-transcription PCR; AUROC: area under receptor-operated curve; tsRNAs: tRNA-derived small RNAs.

References

  1. Gupta, S.; Bent, S.; Kohlwes, J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann. Intern. Med. 2003, 139, 46–50. [Google Scholar] [CrossRef] [PubMed]
  2. Wang, S.; Wang, J.; Wei, W.; Ma, G. Exosomes: The Indispensable Messenger in Tumor Pathogenesis and the Rising Star in Antitumor Applications. Adv. Biosyst. 2019, 3, e1900008. [Google Scholar] [CrossRef] [PubMed]
  3. Słomka, A.; Kornek, M.; Cho, W.C. Small Extracellular Vesicles and Their Involvement in Cancer Resistance: An Up-to-Date Review. Cells 2022, 11, 2913. [Google Scholar] [CrossRef] [PubMed]
  4. Jiang, C.; Fu, Y.; Liu, G.; Shu, B.; Davis, J.; Tofaris, G.K. Multiplexed Profiling of Extracellular Vesicles for Biomarker Development. Nano-Micro Lett. 2021, 14, 3. [Google Scholar] [CrossRef] [PubMed]
  5. Vaidyanathan, R.; Soon, R.H.; Zhang, P.; Jiang, K.; Lim, C.T. Cancer diagnosis: From tumor to liquid biopsy and beyond. Lab Chip 2018, 19, 11–34. [Google Scholar] [CrossRef]
  6. Zhu, L.; Sun, H.T.; Wang, S.; Huang, S.L.; Zheng, Y.; Wang, C.Q.; Hu, B.Y.; Qin, W.; Zou, T.T.; Fu, Y.; et al. Isolation and characterization of exosomes for cancer research. J. Hematol. Oncol. 2020, 13, 152. [Google Scholar] [CrossRef]
  7. Fan, Z.; Yu, J.; Lin, J.; Liu, Y.; Liao, Y. Exosome-specific tumor diagnosis via biomedical analysis of exosome-containing microRNA biomarkers. Analyst 2019, 144, 5856–5865. [Google Scholar] [CrossRef]
  8. Kosaka, N.; Iguchi, H.; Yoshioka, Y.; Takeshita, F.; Matsuki, Y.; Ochiya, T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 2010, 285, 17442–17452. [Google Scholar] [CrossRef]
  9. Li, W.; Li, C.; Zhou, T.; Liu, X.; Liu, X.; Li, X.; Chen, D. Role of exosomal proteins in cancer diagnosis. Mol. Cancer 2017, 16, 145. [Google Scholar] [CrossRef]
  10. Rayamajhi, S.; Nguyen, T.; Marasini, R.; Aryal, S. Macrophage-derived exosome-mimetic hybrid vesicles for tumor targeted drug delivery. Acta Biomater. 2019, 94, 482–494. [Google Scholar] [CrossRef]
  11. Skotland, T.; Hessvik, N.P.; Sandvig, K.; Llorente, A. Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology. J. Lipid Res. 2019, 60, 9–18. [Google Scholar] [CrossRef]
  12. Ohno, S.; Drummen, G.P.; Kuroda, M. Focus on Extracellular Vesicles: Development of Extracellular Vesicle-Based Therapeutic Systems. Int. J. Mol. Sci. 2016, 17, 172. [Google Scholar] [CrossRef] [PubMed]
  13. Barile, L.; Vassalli, G. Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol. Ther. 2017, 174, 63–78. [Google Scholar] [CrossRef]
  14. Dai, J.; Su, Y.; Zhong, S.; Cong, L.; Liu, B.; Yang, J.; Tao, Y.; He, Z.; Chen, C.; Jiang, Y. Exosomes: Key players in cancer and potential therapeutic strategy. Signal Transduct. Target. Ther. 2020, 5, 145. [Google Scholar] [CrossRef] [PubMed]
  15. Zhan, F.; Shen, J.; Wang, R.; Wang, L.; Dai, Y.; Zhang, Y.; Huang, X. Role of exosomal small RNA in prostate cancer metastasis. Cancer Manag. Res. 2018, 10, 4029–4038. [Google Scholar] [CrossRef] [PubMed]
  16. Pan, Q.; Zhao, J.; Li, M.; Liu, X.; Xu, Y.; Li, W.; Wu, S.; Su, Z. Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing. Carcinogenesis 2020, 41, 18–24. [Google Scholar] [CrossRef]
  17. Sasaki, R.; Kanda, T.; Yokosuka, O.; Kato, N.; Matsuoka, S.; Moriyama, M. Exosomes and Hepatocellular Carcinoma: From Bench to Bedside. Int. J. Mol. Sci. 2019, 20, 1406. [Google Scholar] [CrossRef]
  18. Chun, Y.S.; Pawlik, T.M.; Vauthey, J.N. 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers. Ann. Surg. Oncol. 2018, 25, 845–847. [Google Scholar] [CrossRef]
  19. Rui, T.; Zhang, X.; Feng, S.; Huang, H.; Zhan, S.; Xie, H.; Zhou, L.; Zheng, S.; Ling, Q. MiR-516a-3p is a Novel Mediator of Hepatocellular Carcinoma Oncogenic Activity and Cellular Metabolism. Engineering 2021, 16, 162–175. [Google Scholar] [CrossRef]
  20. Langmead, B.; Trapnell, C.; Pop, M.; Salzberg, S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009, 10, R25. [Google Scholar] [CrossRef]
  21. Kozomara, A.; Griffiths-Jones, S. miRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014, 42, D68–D73. [Google Scholar] [CrossRef] [PubMed]
  22. Friedländer, M.R.; Mackowiak, S.D.; Li, N.; Chen, W.; Rajewsky, N. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res. 2012, 40, 37–52. [Google Scholar] [CrossRef]
  23. Wen, M.; Shen, Y.; Shi, S.; Tang, T. miREvo: An integrative microRNA evolutionary analysis platform for next-generation sequencing experiments. BMC Bioinform. 2012, 13, 140. [Google Scholar] [CrossRef] [PubMed]
  24. Rui, T.; Zhang, X.; Feng, S.; Huang, H.; Zhan, S.; Xie, H.; Zhou, L.; Ling, Q.; Zheng, S. The Similar Effects of miR-512-3p and miR-519a-2-5p on the Promotion of Hepatocellular Carcinoma: Different Tunes Sung with Equal Skill. Front. Oncol. 2020, 10, 1244. [Google Scholar] [CrossRef] [PubMed]
  25. Crowley, E.; Di Nicolantonio, F.; Loupakis, F.; Bardelli, A. Liquid biopsy: Monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 2013, 10, 472–484. [Google Scholar] [CrossRef]
  26. Matsui, T.; Nishikawa, K.; Yukimoto, H.; Katsuta, K.; Nakamura, Y.; Tanaka, S.; Oiwa, M.; Nakahashi, H.; Shomi, Y.; Haruki, Y.; et al. Needle tract seeding following endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer: A report of two cases. World J. Surg. Oncol. 2019, 17, 134. [Google Scholar] [CrossRef]
  27. Durand, F.; Belghiti, J.; Paradis, V. Liver transplantation for hepatocellular carcinoma: Role of biopsy. Liver Transpl. 2007, 13, S17–S23. [Google Scholar] [CrossRef]
  28. Ahmadi, S.A.; Moinfar, M.; Gohari Moghaddam, K.; Bahadori, M. Practical application of angiogenesis and vasculogenic mimicry in prostatic adenocarcinoma. Arch. Iran. Med. 2010, 13, 498–503. [Google Scholar]
  29. Maspes, A.; Pizzetti, F.; Rossetti, A.; Makvandi, P.; Sitia, G.; Rossi, F. Advances in Bio-Based Polymers for Colorectal CancerTreatment: Hydrogels and Nanoplatforms. Gels 2021, 7, 6. [Google Scholar] [CrossRef]
  30. Pegtel, D.M.; Gould, S.J. Exosomes. Annu. Rev. Biochem. 2019, 88, 487–514. [Google Scholar] [CrossRef]
  31. Kalluri, R.; LeBleu, V.S. The biology, function, and biomedical applications of exosomes. Science 2020, 367, eaau6977. [Google Scholar] [CrossRef]
  32. Cai, Q.; He, B.; Wang, S.; Fletcher, S.; Niu, D.; Mitter, N.; Birch, P.; Jin, H. Message in a Bubble: Shuttling Small RNAs and Proteins Between Cells and Interacting Organisms Using Extracellular Vesicles. Annu. Rev. Plant Biol. 2021, 72, 497–524. [Google Scholar] [CrossRef]
  33. He, B.; Cai, Q.; Qiao, L.; Huang, C.Y.; Wang, S.; Miao, W.; Ha, T.; Wang, Y.; Jin, H. RNA-binding proteins contribute to small RNA loading in plant extracellular vesicles. Nat. Plants 2021, 7, 342–352. [Google Scholar] [CrossRef]
  34. Gorji-Bahri, G.; Hashemi, A.; Moghimi, H.R. ExomiRs: A Novel Strategy in Cancer Diagnosis and Therapy. Curr. Gene Ther. 2018, 18, 336–350. [Google Scholar] [CrossRef]
  35. Li, S.; Yi, M.; Dong, B.; Tan, X.; Luo, S.; Wu, K. The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. Int. J. Cancer 2021, 148, 2640–2651. [Google Scholar] [CrossRef]
  36. Jalalian, S.H.; Ramezani, M.; Jalalian, S.A.; Abnous, K.; Taghdisi, S.M. Exosomes, new biomarkers in early cancer detection. Anal. Biochem. 2019, 571, 1–13. [Google Scholar] [CrossRef]
  37. Sorop, A.; Constantinescu, D.; Cojocaru, F.; Dinischiotu, A.; Cucu, D.; Dima, S.O. Exosomal microRNAs as Biomarkers and Therapeutic Targets for Hepatocellular Carcinoma. Int. J. Mol. Sci. 2021, 22, 4997. [Google Scholar] [CrossRef]
  38. Zhu, L.; Li, J.; Gong, Y.; Wu, Q.; Tan, S.; Sun, D.; Xu, X.; Zuo, Y.; Zhao, Y.; Wei, Y.Q.; et al. Exosomal tRNA-derived small RNA as a promising biomarker for cancer diagnosis. Mol. Cancer 2019, 18, 74. [Google Scholar] [CrossRef]
  39. Xue, X.; Zhao, Y.; Wang, X.; Qin, L.; Hu, R. Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma. J. Cell. Biochem. 2019, 120, 135–142. [Google Scholar] [CrossRef]
  40. Yang, X.; Sun, L.; Wang, L.; Yao, B.; Mo, H.; Yang, W. LncRNA SNHG7 accelerates the proliferation, migration and invasion of hepatocellular carcinoma cells via regulating miR-122-5p and RPL4. Biomed. Pharmacother. 2019, 118, 109386. [Google Scholar] [CrossRef]
  41. Rao, D.; Guan, S.; Huang, J.; Chang, Q.; Duan, S. miR-425-5p Acts as a Molecular Marker and Promoted Proliferation, Migration by Targeting RNF11 in Hepatocellular Carcinoma. Biomed. Res. Int. 2020, 2020, 6530973. [Google Scholar] [CrossRef] [PubMed]
  42. Wu, H.; Shang, J.; Zhan, W.; Liu, J.; Ning, H.; Chen, N. miR-425-5p promotes cell proliferation, migration and invasion by directly targeting FOXD3 in hepatocellular carcinoma cells. Mol. Med. Rep. 2019, 20, 1883–1892. [Google Scholar] [CrossRef] [PubMed]
  43. Chen, Y.N.; Ren, C.C.; Yang, L.; Nai, M.M.; Xu, Y.M.; Zhang, F.; Liu, Y. MicroRNA let-7d-5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1. Int. J. Oncol. 2019, 54, 1771–1784. [Google Scholar] [CrossRef]
  44. Xie, F.; Xiao, P.; Chen, D.; Xu, L.; Zhang, B. miRDeepFinder: A miRNA analysis tool for deep sequencing of plant small RNAs. Plant Mol. Biol. 2012, 80, 75–84. [Google Scholar] [CrossRef] [PubMed]
  45. Zhang, T.; Ju, L.; Zhai, J.; Song, Y.; Song, J.; Ma, C. miRLocator: A Python Implementation and Web Server for Predicting miRNAs from Pre-miRNA Sequences. Methods Mol. Biol. 2019, 1932, 89–97. [Google Scholar]
Cancers 15 00205 g001
Figure 1. Profiling and analyzing the exosome-derived small RNAs in the serum of HCC patients and non-tumor donors. (A): The schematic diagrams illustrate the procedure of exosome-derived small RNAs’ collection from HCC patients. (B): The transmission electron micrograph depicts the serum exosomes isolated from HCC patients. (C): Four typical exosome markers are detected from proteins extracted from isolated exosomes by Western blot. (D): The proportions of various types of small RNAs in serum exosomes from HCC patients and non-tumor donors.
Figure 1. Profiling and analyzing the exosome-derived small RNAs in the serum of HCC patients and non-tumor donors. (A): The schematic diagrams illustrate the procedure of exosome-derived small RNAs’ collection from HCC patients. (B): The transmission electron micrograph depicts the serum exosomes isolated from HCC patients. (C): Four typical exosome markers are detected from proteins extracted from isolated exosomes by Western blot. (D): The proportions of various types of small RNAs in serum exosomes from HCC patients and non-tumor donors.
Cancers 15 00205 g001
Cancers 15 00205 g002
Figure 2. sRNAs’ length distribution of serum exosomes from four HCC patients and four non tumor donors.
Figure 2. sRNAs’ length distribution of serum exosomes from four HCC patients and four non tumor donors.
Cancers 15 00205 g002
Cancers 15 00205 g003
Figure 3. The training set detects that three serum-exosome-derived miRNAs can be used for diagnosing HCC. (A): The volcano plot shows the differentially expressed serum-exosome-derived miRNAs in HCC patients compared with non-tumor donors. Data are from the small RNAs sequencing. (B–D): The expression levels of the three serum-exosome-derived miRNAs in the training set (55 HCC patients and 20 non-tumor donors). (B): miR-425-5p; (C): let-7d-5p; (D): miR-122-5p. (E,F): The area under the receptor-operated curve (AUROC) depicts the values of the three serum-exosome-derived miRNAs in the diagnosis of HCC in the training set. *, **, and **** were used to represent p value of <0.05, <0.01, and <0.0001, respectively.
Figure 3. The training set detects that three serum-exosome-derived miRNAs can be used for diagnosing HCC. (A): The volcano plot shows the differentially expressed serum-exosome-derived miRNAs in HCC patients compared with non-tumor donors. Data are from the small RNAs sequencing. (B–D): The expression levels of the three serum-exosome-derived miRNAs in the training set (55 HCC patients and 20 non-tumor donors). (B): miR-425-5p; (C): let-7d-5p; (D): miR-122-5p. (E,F): The area under the receptor-operated curve (AUROC) depicts the values of the three serum-exosome-derived miRNAs in the diagnosis of HCC in the training set. *, **, and **** were used to represent p value of <0.05, <0.01, and <0.0001, respectively.
Cancers 15 00205 g003
Cancers 15 00205 g004
Figure 4. Three serum-exosome-derived miRNAs are significant biomarkers for HCC diagnosis. (A–C): qRT-PCR detects the expression levels of the three serum-exosome-derived miRNAs in 69 HCC patients and 26 non-tumor donors (validation set). (A): miR-425-5p; (B): let-7d-5p; (C): miR-122-5p. (D,E): Validation set confirms the high value of the three serum-exosome-derived miRNAs in the diagnosis of HCC. * and **** were used to represent p value of <0.05 and <0.0001, respectively.
Figure 4. Three serum-exosome-derived miRNAs are significant biomarkers for HCC diagnosis. (A–C): qRT-PCR detects the expression levels of the three serum-exosome-derived miRNAs in 69 HCC patients and 26 non-tumor donors (validation set). (A): miR-425-5p; (B): let-7d-5p; (C): miR-122-5p. (D,E): Validation set confirms the high value of the three serum-exosome-derived miRNAs in the diagnosis of HCC. * and **** were used to represent p value of <0.05 and <0.0001, respectively.
Cancers 15 00205 g004
Cancers 15 00205 g005
Figure 5. Three serum-exosome-derived miRNAs have significant values for the early diagnosis of HCC. (A–C): The expression of the three serum-exosome-derived miRNAs in non-tumor donors, low-stage HCC patients, and high-stage HCC patients. (A): miR-122-5p; (B): let-7d-5p; (C): miR-425-5p. (D,E): The value of the three serum-exosome-derived miRNAs for diagnosing low-stage (D) or high-stage HCC (E). *, **, and *** were used to represent p value of <0.05, <0.01, and <0.001, respectively.
Figure 5. Three serum-exosome-derived miRNAs have significant values for the early diagnosis of HCC. (A–C): The expression of the three serum-exosome-derived miRNAs in non-tumor donors, low-stage HCC patients, and high-stage HCC patients. (A): miR-122-5p; (B): let-7d-5p; (C): miR-425-5p. (D,E): The value of the three serum-exosome-derived miRNAs for diagnosing low-stage (D) or high-stage HCC (E). *, **, and *** were used to represent p value of <0.05, <0.01, and <0.001, respectively.
Cancers 15 00205 g005
Cancers 15 00205 sch001
Scheme 1. Serum-exosome-derived miRNAs are of great value in the diagnosis of HCC. Through exosome purification, sRNA sequencing, and qRT-PCR, three serum-exosome-derived miRNAs can be biomarkers for the diagnosis of HCC.
Scheme 1. Serum-exosome-derived miRNAs are of great value in the diagnosis of HCC. Through exosome purification, sRNA sequencing, and qRT-PCR, three serum-exosome-derived miRNAs can be biomarkers for the diagnosis of HCC.
Cancers 15 00205 sch001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rui, T.; Zhang, X.; Guo, J.; Xiang, A.; Tang, N.; Liu, J.; Mao, Z. Serum-Exosome-Derived miRNAs Serve as Promising Biomarkers for HCC Diagnosis. Cancers 2023, 15, 205. https://doi.org/10.3390/cancers15010205

AMA Style

Rui T, Zhang X, Guo J, Xiang A, Tang N, Liu J, Mao Z. Serum-Exosome-Derived miRNAs Serve as Promising Biomarkers for HCC Diagnosis. Cancers. 2023; 15(1):205. https://doi.org/10.3390/cancers15010205

Chicago/Turabian Style

Rui, Tao, Xiaobing Zhang, Jufeng Guo, Aizhai Xiang, Ning Tang, Jian Liu, and Zonglei Mao. 2023. "Serum-Exosome-Derived miRNAs Serve as Promising Biomarkers for HCC Diagnosis" Cancers 15, no. 1: 205. https://doi.org/10.3390/cancers15010205

APA Style

Rui, T., Zhang, X., Guo, J., Xiang, A., Tang, N., Liu, J., & Mao, Z. (2023). Serum-Exosome-Derived miRNAs Serve as Promising Biomarkers for HCC Diagnosis. Cancers, 15(1), 205. https://doi.org/10.3390/cancers15010205

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop